Skip to main
AXSM
AXSM logo

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. is positioned favorably due to the strong momentum of its lead product, Auvelity, in managing major depressive disorder (MDD), supported by its novel mechanism of action and rapid onset of efficacy. Recent progress with AXS-05, including received FDA meeting minutes that outline a path for sNDA submission aimed at agitation in Alzheimer's disease, enhances confidence in its potential approval based on robust clinical trial outcomes demonstrating significant improvements in agitation symptoms. Additionally, the upcoming SYMBRAVO launch, which has shown rapid efficacy in migraine relief and enhanced quality of life metrics through controlled trials, is set to bolster Axsome's market presence and drive future growth.

Bears say

Axsome Therapeutics faces significant risks that negatively impact its outlook, including potential lower-than-expected market access for its product AUVELITY and setbacks in clinical trials, particularly for AXS-05 intended for treatment-resistant depression and smoking cessation. Additionally, the company's ability to secure timely approvals for its pipeline candidates AXS-12 and AXS-14 is uncertain, which could hinder its overall commercial success amidst anticipated competition. The presence of adverse events and the possibility of long-term dilution risk further compound the concerns regarding its financial stability and market performance.

Axsome Therapeutics (AXSM) has been analyzed by 24 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 24 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $145.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $145.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.